Sökning: (WFRF:(Holmberg Lars)) srt2:(2020) >
Spironolactone use ...
Spironolactone use is associated with lower prostate cancer risk : a population-wide case-control study
-
- Beckmann, Kerri (författare)
- Kings Coll London, Sch Canc & Pharmaceut Studies, TOUR, London, England.;Univ South Australia, Canc Res Inst, Adelaide, SA, Australia.
-
- Garmo, Hans (författare)
- Uppsala Univ Hosp, Reg Canc Ctr Uppsala, Uppsala, Sweden.
-
- Lindahl, Bertil, 1957- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
visa fler...
-
- Holmberg, Lars (författare)
- Uppsala universitet,Endokrinkirurgi
-
- Stattin, Pär (författare)
- Uppsala universitet,Urologkirurgi
-
- Adolfsson, Jan (författare)
- Karolinska Institutet
-
- Cruickshank, J. Kennedy (författare)
- Kings Coll London, Sch Life Course Sci, Dept Nutr Studies, London, England.
-
- Van Hemelrijck, Mieke (författare)
- Kings Coll London, Sch Canc & Pharmaceut Studies, TOUR, London, England.;Karolinska Inst, Inst Environm Med, Unit Epidemiol, Stockholm, Sweden.
-
visa färre...
-
Kings Coll London, Sch Canc & Pharmaceut Studies, TOUR, London, England;Univ South Australia, Canc Res Inst, Adelaide, SA, Australia. Uppsala Univ Hosp, Reg Canc Ctr Uppsala, Uppsala, Sweden. (creator_code:org_t)
- 2020-03-02
- 2020
- Engelska.
-
Ingår i: Prostate Cancer and Prostatic Diseases. - : NATURE PUBLISHING GROUP. - 1365-7852 .- 1476-5608. ; 23:3, s. 527-533
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Spironolactone, a cheap effective diuretic used to manage hypertension and heart failure, also has anti-androgenic effects through its non-selective binding to steroid receptors, and hence may affect prostate cancer (PCa) risk. This study investigated the association between spironolactone use and PCa risk. For comparison, we also examined associations with thiazide diuretics which do not have anti-androgenic properties. Methods A matched case-control study was undertaken using population-wide data from the Prostate Cancer Data Base Sweden (PCBaSe). All PCa cases diagnosed from 2014 to 2016 were matched by birth year and county with PCa-free controls selected from the general population (1:5). Multivariable conditional logistic regression was used to examine associations between spironolactone use (dose and duration) and PCa risk, and similarly for thiazides. Results Three percent of the 31,591 cases and 4% of the 156,802 controls had been prescribed spironolactone. Multivariable analyses indicated reduced risk of PCa among those ever exposed to spironolactone (odds ratio [OR] 0.83; 95% confidence interval [CI]: 0.76-0.89), with a stronger association for current users (OR: 0.77, 95% CI: 0.69-0.86) than past users (OR: 0.88; 95% CI: 0.79-0.97) and decreasing risk with increasing dose (p-trend < 0.001). No association was observed for thiazide exposure and PCa risk. Biases due to differences in prescribing patterns or frequency of PSA testing may have influenced these findings. Conclusion PCa risk was reduced among men exposed to the diuretic spironolactone. Further investigation of spironolactone's potential chemopreventive effects is warranted.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas